Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes; New Report Launched
The breast cancer pipeline is the largest in the pharmaceutical industry, with 1,050 products in active development across all stages. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison to the existing market landscape. The degree and proportion of breakthrough innovations in this pipeline is exceptional – Publisher analysis identified 333 first-in-class programs in the breast cancer pipeline, acting on 251 first-in-class molecular targets. This accounts for some 39% of all products...
View full press release